Literature DB >> 22552626

Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression.

Nam-Hee Kang1, Kyung-A Hwang, Tae-Hee Kim, Sang-Hwan Hyun, Eui-Bae Jeung, Kyung-Chul Choi.   

Abstract

Resveratrol (trans-3,4',5-trihydroxystilbene; RES), a phytoestrogen, exists in grape skin and red wine. Endocrine disrupting chemicals (EDCs) appear to promote the development and progression of estrogen-dependent cancers. In this study, we evaluated the inhibitory effect of RES on the cell proliferation induced by various EDCs in BG-1 ovarian cancer cells. Various EDCs, such as bisphenol A (BPA), nonylphenol (NP), octylphenol (OP), methoxychlor (MXC) and hexabromocyclododecane (HBCD), were employed in this study. In the in vitro experiments, treatment of BG-1 cells with E2, BPA, NP, OP, MXC or HBCD resulted in an increase of cell growth. By contrast, increased cell viability induced by these EDCs was reversed when co-cultured with RES. In addition, we examined the regulation of cell cycle-related genes by RT-PCR and western blot analysis. Treatment with each EDC was found to decrease only the gene expression of p21 and increase the expression of cell cycle-dependent kinase 2 (CDK2). However, co-treatment with RES and each EDC resulted in an increased gene expression of p21 and a decreased expression of CDK2. Cyclin D1 was increased by downregulating p21 only when treated with each EDC in the absence of RES, while co-treatment with RES and each EDC decreased the gene expression of cyclin D1 by upregulating p21. Taken together, RES appears to be an inhibitor of cyclin D1 and CDK2 and is responsible for the cell cycle arrest at the G1 phase. In addition, when co-treated with each EDC, RES increased the expression of p21 and resulted in the growth inhibition of BG-1 ovarian cancer cells. Taken together, these results indicate the antiproliferative effect of RES, a dietary phytoestrogen, on estrogen-dependent ovarian cancer cells activated by EDCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552626     DOI: 10.3892/mmr.2012.887

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Update of the risk assessment of hexabromocyclododecanes (HBCDDs) in food.

Authors:  Dieter Schrenk; Margherita Bignami; Laurent Bodin; James Kevin Chipman; Jesús Del Mazo; Bettina Grasl-Kraupp; Christer Hogstrand; Laurentius Ron Hoogenboom; Jean-Charles Leblanc; Carlo Stefano Nebbia; Elsa Nielsen; Evangelia Ntzani; Annette Petersen; Salomon Sand; Tanja Schwerdtle; Heather Wallace; Diane Benford; Peter Fürst; Martin Rose; Sofia Ioannidou; Marina Nikolič; Luisa Ramos Bordajandi; Christiane Vleminckx
Journal:  EFSA J       Date:  2021-03-08

2.  Research Resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant.

Authors:  Yin Li; Yukitomo Arao; Julie M Hall; Sandra Burkett; Liwen Liu; Kevin Gerrish; Vincent Cavailles; Kenneth S Korach
Journal:  Mol Endocrinol       Date:  2014-12

Review 3.  Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors.

Authors:  Hye-Rim Lee; Eui-Bae Jeung; Myung-Haing Cho; Tae-Hee Kim; Peter C K Leung; Kyung-Chul Choi
Journal:  J Cell Mol Med       Date:  2012-12-20       Impact factor: 5.310

4.  Treatment of BG-1 Ovarian Cancer Cells Expressing Estrogen Receptors with Lambda-cyhalothrin and Cypermethrin Caused a Partial Estrogenicity Via an Estrogen Receptor-dependent Pathway.

Authors:  Cho-Won Kim; Ryeo-Eun Go; Kyung-Chul Choi
Journal:  Toxicol Res       Date:  2015-12

5.  Bisphenol-A and Nonylphenol Induce Apoptosis in Reproductive Tract Cancer Cell Lines by the Activation of ADAM17.

Authors:  Paulina Urriola-Muñoz; Raúl Lagos-Cabré; Daniel Patiño-García; Juan G Reyes; Ricardo D Moreno
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.